The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index; none of the 32 sources its claims cite is checked for support yet.
Bacteroides vulgatus and Bacteroides dorei Reduce Gut Microbial Lipopolysaccharide Production and Inhibit Atherosclerosis
Abstract
Background: It is increasingly recognized that gut microbiota play a pivotal role in the development of atherosclerotic cardiovascular disease. Previously, we have reported that the abundance of genus Bacteroides is lower in patients with coronary artery disease (CAD) than in patients without CAD with coronary risk factors or in healthy volunteers. However, it remains unclear which and how specific gut bacteria contribute to the progression of atherosclerosis. Methods: We recruited patients with CAD patients and controls without CAD with coronary risk factors. We then compared gut microbial composition using 16S ribosomal RNA gene sequencing in fecal samples to detect species with differential abundance between 2 groups. Subsequently, we used atherosclerosis-prone mice to study the mechanisms underlying the relationship between such species and atherosclerosis. Results: Human fecal 16S ribosomal RNA gene sequencing revealed a significantly lower abundance of Bacteroides vulgatus and Bacteroides dorei in patients with CAD. This significant differential abundance was confirmed by quantitative polymerase chain reaction. Gavage with live B. vulgatus and B. dorei attenuated atherosclerotic lesion formation in atherosclerosis-prone mice, markedly ameliorating endotoxemia followed by decreasing gut microbial lipopolysaccharide production, effectively suppressing proinflammatory immune responses. Furthermore, fecal lipopolysaccharide levels in patients with CAD were significantly higher and negatively correlated with the abundance of B. vulgatus and B. dorei . Conclusions: Our translational research findings identify a previously unknown link between specific gut bacteria and atherosclerosis. Treatment with live B. vulgatus and B. dorei may help prevent CAD. Clinical Trial Registration: URL: https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018051 . Unique identifier: UMIN000015703.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In patients with coronary artery disease (CAD), gut abundance of *Bacteroides vulgatus* and *Bacteroides dorei* was lower than in controls without CAD, and fecal lipopolysaccharide (LPS) levels were higher. In atherosclerosis-prone mice, oral gavage with live *B. vulgatus* and *B. dorei* reduced fecal and plasma LPS, dampened inflammation, and attenuated atherosclerotic plaque.
Key findings
- In 30 patients with CAD versus 30 age- and sex-matched controls without CAD but with coronary risk factors, 16S rRNA sequencing showed relative depletion of *B. vulgatus* and *B. dorei* in CAD; qPCR confirmed significantly decreased abundance of these species.
- Fecal LPS levels were significantly higher in patients with CAD than controls, and fecal LPS correlated negatively with *B. vulgatus*/*B. dorei* abundance in CAD (r=−0.541, P=0.002); genus *Bacteroides* showed a trend toward negative correlation (r=−0.227, P=0.0838).
- In apolipoprotein E-deficient mice, gavage with live *B. vulgatus* and *B. dorei* (2.5×10⁹ cfu/100 μL, 5 times/week) significantly reduced aortic root and en face atherosclerotic lesion size, macrophage and CD4⁺ T-cell accumulation, plasma LPS, and proatherogenic cytokines, without significant differences in body weight, plasma cholesterol, or plasma glucose.
- Live *Bacteroides* treatment decreased predicted microbial LPS biosynthesis genes *LpxA* and *LpxD* and dramatically lowered fecal LPS; heat-killed *Bacteroides* did not decrease fecal LPS, aortic sinus plaque, or plasma LPS compared with controls (reported P=0.92, P=0.74, and P=0.93, respectively).
Methods
- Human study: 30 patients with CAD and 30 controls without CAD with coronary risk factors were recruited at Kobe University Hospital between October 2014 and July 2015; fecal samples underwent 16S rRNA gene sequencing (V3–V4 region), qPCR, PICRUSt functional prediction, and limulus amebocyte lysate assay for LPS.
- Mouse study: 6-week-old female apolipoprotein E-deficient mice on C57BL/6 background were randomized to control, live *Bacteroides*, or heat-killed *Bacteroides* groups; mice were gavaged 5 times per week for 10 weeks and euthanized at 16 weeks for atherosclerosis, immune, gut permeability, and LPS analyses.
- Statistical analysis used R, JMP, and Prism; Shapiro-Wilk test, Student’s t test or Mann-Whitney U test, Fisher exact or χ² test, Spearman correlation, one-way ANOVA, and Benjamini-Hochberg adjustment for multiple comparisons.
Limitations
- The paper states that 16S rRNA sequencing has low phylogenetic power at the species level and poor discriminatory power for some genera, and that the human CAD gut microbial analysis was a single-center study with a relatively small number of patients.
- The paper states that controls without CAD did not all undergo coronary angiography, so subclinical CAD may have been present; the limulus amebocyte lysate assay could not measure LPS immunogenicity or the impact of *Bacteroides* on LPS structure/function; mechanisms of atherosclerosis protection by lower LPS were not completely elucidated; mouse and human dominant microbiota differ; and only *B. vulgatus* and *B. dorei* were tested, so more effective strains may exist.
- Evident from the text: the human findings are cross-sectional and cannot establish causality, and the causal evidence comes from a mouse gavage model rather than a human intervention.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 32 cited sources checked · 0 supported · 0 flagged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“immunohistochemical staining followed by morphometric analysis of atherosclerotic lesions in the aortic sinus revealed a marked reduction in macrophage and CD4 + T-cell accumulation in mice gavaged with live Bacteroides compared with controls (Figure 2C and 2D).”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gut Microbial Profile in Patients With CAD
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“we observed significantly higher expression levels of ZO-1 (mRNA and protein) in HT29 cells stimulated with fecal supernatant from live Bacteroides-treated mice than in cells stimulated with fecal supernatant from control mice (Figure VD and VE in the online-only Data Supplement).”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Live Bacteroides Treatment Strengthened Tight Junction Formation In Vivo and In Vitro
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“we found that the abundance of Bacteroides vulgatus and Bacteroides dorei was decreased in patients with CAD.”
- Also stated in: § Gut Microbial Profile in Patients With CAD · plain
“patients with CAD showed a relative depletion of B. vulgatus and B. dorei”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § Gut Microbial Profile in Patients With CAD · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The mRNA expression of several proatherogenic immune cell markers and chemokines/ chemokine receptors was decreased in mice gavaged with live Bacteroides (Figure 2E).”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gut Microbial Profile in Patients With CAD
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“reflected in higher mean fluorescence intensity of ZO-1 in the colon (Figure VC in the online-only Data Supplement).”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Live Bacteroides Treatment Strengthened Tight Junction Formation In Vivo and In Vitro
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although the expression of genes related to TMA synthesis (CutC, CutD) had no difference among the groups”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gavage With Live Bacteroides Alters Gut Microbial LPS Production
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We found that the relative abundance of the genus Bacteroides was visibly lower in patients with CAD compared with controls (Figure 1G).”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gut Microbial Profile in Patients With CAD
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The abundance of B. vulgatus and B. dorei was considerably higher in feces from live Bacteroides-gavaged mice (Figure IIIF in the online-only Data Supplement).”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gavage With Live Bacteroides Alters Gut Microbial LPS Production
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“the expression of genes involved in LPS biosynthesis, especially LpxA and LpxD, which are involved in lipid A biosynthesis and constitute the essential acyltransferases of the lipid A structure (Figure 3B), 38,39 was significantly decreased in mice gavaged with live Bacteroides (Figure 3A and 3C, Figure IV in the online-only Data Supplement).”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gavage With Live Bacteroides Alters Gut Microbial LPS Production
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We also confirmed the significantly decreased abundance of B. vulgatus and B. dorei in patients with CAD by quantitative polymerase chain reaction (Figure 1J and Table II in the online-only Data Supplement).”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gut Microbial Profile in Patients With CAD
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- It may state two separate claims as one. 29
- Probably not a substantial claim. 21
- The quote only partly states this claim. 2
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“mice gavaged with Bacteroides exhibited decreased expression of major histocompatibility complex class II and costimulatory molecule CD86, as well as increased expression of the coinhibitory molecules programmed death ligand-1 and programmed death ligand-2 on splenic CD11c high dendritic cells (Figure IIB in the online-only Data Supplement).”
- Also stated in: § ORIGINAL RESEARCH ARTICLE · plain
“Similar phenotypic changes along with increased expression of PD-L1 and PD-L2 in dendritic cells were observed in the spleen.”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > ORIGINAL RESEARCH ARTICLE
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Also stated in: § ORIGINAL RESEARCH ARTICLE · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the samples were clustered into 3 clusters at the genus level”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gut Microbial Profile in Patients With CAD
Strength:plain· not yet calibratedn = 30Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“mice gavaged with live Bacteroides showed significantly reduced lesion size in the aortic root and en face analysis of thoracoabdominal aortas (Figure 2A and 2B)”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gut Microbial Profile in Patients With CAD
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The controls without CAD were significantly more likely to be categorized into cluster 1, whereas few patients with CAD were categorized into this cluster (Figure 1F).”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gut Microbial Profile in Patients With CAD
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“without significant difference in body weight (Figure 2F), plasma cholesterol levels (Figure 2G), or plasma glucose levels (data not shown).”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gut Microbial Profile in Patients With CAD
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Each cluster was characterized by a high abundance of a specific genus as follows: Bacteroides in cluster 1, Prevotella in cluster 2, and Faecalibacterium, Ruminococcus, or Bifidobacterium in cluster 3 (Figure 1E).”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gut Microbial Profile in Patients With CAD
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Mice gavaged with live Bacteroides had lower numbers of effector CD44 high CD62Llow CD4 + T cells and a significantly higher proportion of CD4 + CD25 + Foxp3 + regulatory T cells, with higher levels of intracellular CTLA4 (Figure IID and IIE in the online-only Data Supplement)”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > ORIGINAL RESEARCH ARTICLE
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“patients with CAD showed a relative depletion of B. vulgatus and B. dorei and enrichment in Faecalibacterium prausnitzii and Prevotella copri (Figure 1H).”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gut Microbial Profile in Patients With CAD
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The α diversity, Bacteroidetes/Firmicutes ratio, and Gram-positive to Gramnegative strain ratio did not differ significantly between the 2 groups (Figure 1A and 1C).”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gut Microbial Profile in Patients With CAD
Strength:plain· not yet calibratedn = 30Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“were the 2 most abundant species within the genus Bacteroides in 16S rRNA gene sequencing analysis (Figure 1I).”
- Also stated in: § DISCUSSION · plain
“B. vulgatus and B. dorei are the dominant species of genus Bacteroides in human gut microbiota.”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gut Microbial Profile in Patients With CAD
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one. The quote only partly states this claim.
- Also stated in: § DISCUSSION · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Bacteroidetes/Firmicutes ratio, Gram-positive to Gram-negative strain ratio, and fecal water content did not differ significantly among the 3 groups”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Affiliations
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“whereas the number of CD4 + T cells and several markers on CD4 + T cells did not significantly change (Figure VIC and VIF in the online-only Data Supplement).”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > ORIGINAL RESEARCH ARTICLE
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“we found that fecal LPS levels were higher in patients with lower abundance of B. vulgatus and B. dorei.”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > DISCUSSION
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesThe quote only partly states this claim.
- Rests on an assumption: Fecal lipopolysaccharide levels reflect colon lipopolysaccharide concentrations produced by gut microbiota.
None of the sources cited for this claim have been checked yet.
In the paper
“Trimethylamine (TMA) and TMA N-oxide, which are gut microbiota metabolites of dietary phosphatidylcholine, are known to be associated with cardiovascular disease and with the atherosclerosis process in particular.3,4”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Abstract
Strength:boosted· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“CAD remains the leading cause of morbidity and mortality worldwide, despite the widespread use of statin therapy in the last decade.12”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Abstract
What the sources say
- Not checked yetcites [12] source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Endotoxemia is known to cause systemic inflammation leading to the disruption of innate and adaptive immunity and the development of atherosclerosis.[34][35][36]”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gut Microbial Profile in Patients With CAD
What the sources say
- Not checked yetcites [34]
- Not checked yetcites [35] source
- Not checked yetcites [36]
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“a recent clinical trial has shown contradictory results indicating that fish consumption drastically increases circulating TMA N-oxide levels”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Abstract
What the sources say
- Not checked yetcites [6] source
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“This study was approved by the Ethics Committee of Kobe University (approval No. 1595) and registered with the University hospital Medical Information Network Clinical Trials Registry (trial registration No. UMIN000015703).”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Recruitment of Patients With CAD and Controls
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The success of the heat treatment was confirmed by the absence of growth of plated heat-killed bacteria.”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Animals
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All participants provided written informed consent on enrollment, and the study was conducted according to the guidelines of the Declaration of Helsinki.”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Recruitment of Patients With CAD and Controls
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All experiments were performed according to the Guidelines for Animal Experiments in effect at Kobe University School of Medicine (guideline No. P160701).”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Animals
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“However, it remains unclear which specific Bacteroides species are involved and what their exact role is in CAD.11”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Abstract
What the sources say
- Not checked yetcites [11]
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Six-week-old mice were randomly divided into 3 treatment groups”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Animals
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“Because these 2 species share similar 16S rRNA sequencing patterns, 32 we were not able to distinguish them using our methodology.”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gut Microbial Profile in Patients With CAD
What the sources say
- Not checked yetcites [32]
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The sample size was calculated using R software (power=0.9,significance level=0.05,mean difference=6, SD=7; n=30 per group.).”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Recruitment of Patients With CAD and Controls
Strength:plain· not yet calibratedn = 30Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“The genus Bacteroides includes some of the predominant gut bacteria in humans and is known to have an important role in maintaining a healthy gut ecosystem.7”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Abstract
What the sources say
- Not checked yetcites [7]
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Because LPS stimulates cells through TLR4 and upregulates costimulatory molecules on antigen-presenting cells, 37”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gut Microbial Profile in Patients With CAD
What the sources say
- Not checked yetcites [37]
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These results suggested that replenishment of live B. vulgatus and B. dorei by oral gavage reduced plaque inflammation, attenuating atherosclerotic lesion formation.”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > Gut Microbial Profile in Patients With CAD
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The effects of live B. vulgatus and B. dorei on atherosclerosis in apolipoprotein E-deficient mice are representative of human coronary artery disease.
None of the sources cited for this claim have been checked yet.
In the paper
“Although LPS from E. coli increases intestinal permeability in a TLR4-dependent manner, 40,41”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > ORIGINAL RESEARCH ARTICLE
What the sources say
- Not checked yetcites [40]
- Not checked yetcites [41]
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“because we did not perform coronary angiography for all the controls without CAD, there might have been individuals with subclinical CAD in the control group”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > ORIGINAL RESEARCH ARTICLE
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“These limitations imply that we did not fully elucidate the characteristics of gut microbial composition in CAD”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > ORIGINAL RESEARCH ARTICLE
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“16S rRNA sequencing analysis helped to seek candidate and translate to animal experiments”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > ORIGINAL RESEARCH ARTICLE
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“Given that gut microbiota-derived LPS and systemic endotoxemia are involved in the onset and progression of not only atherosclerosis but also many prevalent disorders, such as inflammatory bowel disease, obesity and related metabolic diseases, and nonalcoholic steatohepatitis, [47][48][49]”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > ORIGINAL RESEARCH ARTICLE
What the sources say
- Not checked yetcites [47][48][49]
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“the gut microbial analysis in patients with CAD was a single-center study with a relatively small number of patients”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > ORIGINAL RESEARCH ARTICLE
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“used a mouse model to clarify the causal relationship between B. vulgatus and B. dorei and atherosclerosis”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > ORIGINAL RESEARCH ARTICLE
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“the LPS compounds penta-and tetraacylated lipid A of these Bacteroides species are structur-ally distinct from the hexa-acylated LPS of E.scherichia coli and elicit reduced TLR4 responses.33”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > DISCUSSION
What the sources say
- Not checked yetcites [33] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These results strongly support the idea that B. vulgatus and B. dorei regulate gut microbial production of LPS and that their activity can influence the progression of atherosclerosis in patients with CAD.”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > ORIGINAL RESEARCH ARTICLE
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: Fecal lipopolysaccharide levels reflect colon lipopolysaccharide concentrations produced by gut microbiota.
- Rests on an assumption: The effects of live B. vulgatus and B. dorei on atherosclerosis in apolipoprotein E-deficient mice are representative of human coronary artery disease.
None of the sources cited for this claim have been checked yet.
In the paper
“we considered that augmentation of these tolerogenic dendritic cells' phenotype in MLNs or spleen was suspected to migrate into the blood and was closely associated with attenuated atherosclerotic lesion formation as previously reported.42,43,46”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > ORIGINAL RESEARCH ARTICLE
What the sources say
- Not checked yetcites [42]
- Not checked yetcites [43]
- Not checked yetcites [46]
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- The authors state this as an assumption: Decreased circulating lipopolysaccharide levels after live Bacteroides treatment may reduce expression of TLR4, CCR7, CCL17, and CCL21 in the aorta, resulting in less macrophage and CD4+ T cell accumulation in atherosclerotic plaque.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“we performed gavage only with B. vulgatus and B. dorei”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > ORIGINAL RESEARCH ARTICLE
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“we believe that B. vulgatus and B. dorei might improve the enteric environment, providing gut bacteria with good living conditions and having a beneficial effect on bacterial LPS production.”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > DISCUSSION
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“we did not completely elucidate the mechanisms of atherosclerosis protection by lower LPS concentrations in mice”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > ORIGINAL RESEARCH ARTICLE
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“it could not measure LPS immunogenicity and the impact of Bacteroides on the structure and function of LPS”
§ Live Bacteroides Treatment Ameliorated Endotoxemia and Systemic Inflammation > ORIGINAL RESEARCH ARTICLE
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The authors state this as an assumption.
Decreased circulating lipopolysaccharide levels after live Bacteroides treatment may reduce expression of TLR4, CCR7, CCL17, and CCL21 in the aorta, resulting in less macrophage and CD4+ T cell accumulation in atherosclerotic plaque.
“it is intriguing to assume that decreased circulating LPS levels after live Bacteroides treatment may reduce the expression of TLR4, CCR7, CCL17, and CCL21 in the aorta, resulting in less macrophage and CD4 + T cell accumulation in atherosclerotic plaque.”
The paper relies on this without support.
Fecal lipopolysaccharide levels reflect colon lipopolysaccharide concentrations produced by gut microbiota.
“we measured fecal LPS levels as an indicator of colon LPS concentrations pro-duced by gut microbiota.”
The paper relies on this without support.
The effects of live B. vulgatus and B. dorei on atherosclerosis in apolipoprotein E-deficient mice are representative of human coronary artery disease.
“Bacteroides treatment may serve as a novel and attractive therapeutic strategy for suppressing lipopolysaccharide-induced inflammatory response in CAD.”
The paper relies on this without support.
The hospital diet consumed by participants did not confound the gut microbiome or fecal lipopolysaccharide measurements.
“Fecal samples were collected while participants were hospitalized and thus consuming a hospital diet for >1 day.”
The paper relies on this without support.
The impact of colon lipopolysaccharide concentrations on intestinal permeability has not been fully investigated to date.
“the impact of colon LPS concentrations on intestinal permeability has not been fully investigated to date.”
The paper relies on this without support.
A specific gut microbiota-based target to prevent coronary artery disease has yet to emerge.
“a specific gut microbiota-based target to prevent CAD has yet to emerge.”
The paper relies on this without support.
Gut microbial profiles depend on age, sex, local food or lifestyle, and many other factors, making it difficult to define dysbiosis in atherosclerosis.
“it is difficult to conclude the definition of dysbiosis in atherosclerosis because each gut microbial profile depends on age, sex, local food or lifestyle, and many other factors”
The paper relies on this without support.
16S rRNA sequencing analysis has low phylogenetic power at the species level and poor discriminatory power for some genera.
“It has low phylogenetic power at the species level and poor discriminatory power for some genera”
The paper relies on this without support.
The relative abundances of most of the dominant gut microbiota in mice and humans are quite different.
“the relative abundances of most of the dominant gut microbiota in mice and human are quite different”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For instance, gavage with the gram-negative Bacteroides (vulgatus and dorei) that produce penta- and tetra-acylated lipid A – in contrast to the hexa-acylated lipid A of e. coli, reduced colonic inflammation, endotoxemia, and atherosclerosis in ApoE−/− mice31.”
From Gut microbiota and cardiovascular disease. (2020) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Two different articles are assigned the same DOI
MinorReferences 31 and 33 give the identical DOI for articles with different titles, journals, and page ranges. At least one DOI is incorrect.
“Variation in microbiome LPS immunogenicity contributes to autoim- munity in humans. Cell. 2016;165:842-853. doi: 10.1002/art.39783”
“Dysbio- sis contributes to arthritis development via activation of autoreactive T cells in the intestine. Arthritis Rheumatol. 2016;68:2646-2661. doi: 10.1002/art.39783”
Citations
Cites
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548
QIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887
Search and clustering orders of magnitude faster than BLAST
Edgar, R. C. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq461 · Cited by 21,098
Naive Bayesian Classifier for Rapid Assignment of rRNA Sequences into the New Bacterial Taxonomy
Wang, Q., Garrity, G. M., Tiedje, J. M., & Cole, J. R. (2007) · Applied and Environmental Microbiology · doi:10.1128/aem.00062-07 · Cited by 20,145
UPARSE: highly accurate OTU sequences from microbial amplicon reads
Edgar, R. C. (2013) · Nature Methods · doi:10.1038/nmeth.2604 · Cited by 16,770
UCHIME improves sensitivity and speed of chimera detection
Edgar, R. C., Haas, B. J., Clemente, J. C., Quince, C., & Knight, R. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr381 · Cited by 15,114
Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences
Langille, M. G. I., Zaneveld, J., Caporaso, J. G., McDonald, D., Knights, D., Reyes, J. A., Clemente, J. C., Burkepile, D. E., Vega Thurber, R. L., Knight, R., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2676 · Cited by 9,116
KEGG: new perspectives on genomes, pathways, diseases and drugs
Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y., & Morishima, K. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1092 · Cited by 8,865
Enterotypes of the human gut microbiome
MetaHIT Consortium (additional members), Arumugam, M., Raes, J., Pelletier, E., Le Paslier, D., Yamada, T., Mende, D. R., Fernandes, G. R., Tap, J., Bruls, T., et al. (2011) · Nature · doi:10.1038/nature09944 · Cited by 7,548
Self-citationRosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1002/art.39783 · DOI · Paper page
Cited by
Sorted by citations
Items 501–600 of 625
A gut microbial odd-chain fatty acid alleviates atherosclerosis in mice
Yin, C., Chen, Y., Lin, G., Cai, M., Pang, C., Xiao, X., Han, K., Mei, C., Qin, M., 范培芝, et al. (2026) · Nature · doi:10.1038/s41586-026-11142-x · Cited by 2
Li, Y., Ling, Y., Liu, J., Zhang, M., Li, Z., Bai, Z., Wu, Z., Ran, X., Wu, Z., Wan, Y., et al. (2022) · Fermentation · doi:10.3390/fermentation8050210 · Cited by 1
Probiotics for obesity and metabolic syndrome prevention and treatment
Gomes, A. C., Hoffmann, C., & Mota, J. F. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-89908-6.00017-0 · Cited by 1
Gut Microbiota Regulation of Cerebral Stroke
Kumar, K., Hema, K., & Tripathi, A. K. (2022) · Nutritional neurosciences · doi:10.1007/978-981-19-4530-4_4 · Cited by 1
Dutta, A., Pinna, N. K., & Mande, S. S. (2023) · Journal of the Indian Institute of Science · doi:10.1007/s41745-022-00351-8 · Cited by 1
Cheng, Q., Zhang, L., Liu, F., Fan, C., Wu, T., Li, Y., Hou, H., Ma, Y., Tan, Y., Li, Y., et al. (2023) · Human Gene · doi:10.1016/j.humgen.2023.201158 · Cited by 1
Dai, W., Liu, Y., Zhang, X., & Dai, L. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e22369 · Cited by 1
“Lipopolysaccharide (LPS) is a major component of the cell wall of gram-negative bacteria and a stimulant of the intestinal immune system [ [26]].”
BackgroundGut Microbiota and Its Role in Human Metabolic Disorders
Yadav, A., Mohite, S. V., Behl, A., Shinde, P. B., & Sharma, K. K. (2023) · Springer eBooks · doi:10.1007/978-981-99-3126-2_14 · Cited by 1
HIV rebound in HIV controllers is associated with a specific fecal microbiome profile
Cai, Y., Podlaha, O., Deeks, S. G., Brinson, C. C., Ramgopal, M. N., DeJesus, E., Mills, A., Shalit, P., Abdel‐Mohsen, M., Zhang, L., et al. (2024) · European Journal of Immunology · doi:10.1002/eji.202350809 · Cited by 1
“Bacteroides vulgatus is a dominant species of Bacteroides, which has been shown to attenuate the levels of microbial lipopolysaccharide synthesis in mice [31] and could therefore impact lipopolysaccharide synthesis in the human gut, helping to modulate gut immunity.”
Safari‐Alighiarloo, N., Bostanghadiri, N., Sedighi, M., Mohebbi, A., Vafaei, E., Mirshekar, M., Razavi, S., & Alaei-Shahmiri, F. (2024) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2024.0071 · Cited by 2
“25,26 In our study, individuals with preDM or T2DM were obese (BMI = 30.3), while individuals with NGT were overweight (BMI = 26.8).”
InfluentialRole of intestinal flora imbalance in formation of abdominal aortic aneurysms
Wang, X., Yu, J., Tian, C.-H., & Liang, T. (2024) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v32.i12.859 · Cited by 1
Gut Microbiota and Their Metabolites as Modulators of Vascular Complications in Diabetes
Duan, M. Y., Wen, J., Chen, A., & Chen, S. (2025) · Health and Metabolism · doi:10.53941/hm.2025.100002 · Cited by 1
“In the following sections, we delve into how gut microbiota and their metabolites contribute to the development of diabetic cardiovascular disease, nephropathy, retinopathy, and other complications.”
Defining the role of individual gut commensal microbes and host-microbe interactions
Ju, T. (2019) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3-fhw9-mj96 · Cited by 1
Rosso, A. D., Pablo, A., Quesada, S., Cerezo, J., Spiazzi, R. A., Conlon, M. C., Claudia, M., Iraola, G., Leskow, F. C., Steinhardt, A. P., et al. (2020) · medRxiv · doi:10.1101/2020.07.29.20164764 · Cited by 1
“Dorei have been reported to reduce the production of intestinal microbial lipopolysaccharides (LPS) [67].”
BackgroundGut Microbiome Variation in Pulmonary TB Patients with Diabetes or HIV ComorbiditiesPreprint
Morgan, P. A., Parbie, P. K., Ntiamoah, D. O., Boadu, A. A., Asare, P. P. A., Lamptey, I. N. K., Gorman, C. N., Afreh, E. K., Asante-Poku, A., Otchere, I. D., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1756773/v1 · Cited by 1
Yin, L., Jiang, L., Zhou, Z., Zhao, J., Tang, J., & Wang, Z. (2023) · Research Square · doi:10.21203/rs.3.rs-2709801/v1 · Cited by 1
Foster, T. L., & Khaiboullina, S. F. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1193841 · Cited by 1
“Studies have demonstrated that changes in the gut microbiome could contribute to the incidence of coronary artery disease (CAD) (Koeth et al., 2013; Yoshida et al., 2018; Liu et al., 2019).”
BackgroundCao, Y.-H., Zhou, Y.-M., Wang, S., Guo, J., & Cen, L.-S. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i12.2387 · Cited by 1
Вплив пробіотичного харчування при цукровому діабеті 2 типу
Fadieienko, G. D., & Kurinna, O. G. (2020) · doi:10.30978/utj2020-2-43
Gut Microbial Dysbiosis is Correlated with Stroke Severity Markers in Aged Rats Following StrokePreprint
Hammond, T. C., Messmer, S. J., Frank, J. A., Lukins, D. E., Colwell, R. R., Lin, A., & Pennypacker, K. R. (2021) · Research Square · doi:10.21203/rs.3.rs-1044260/v1
Frontiers in inflammation and cardiovascular disease
Hoshiga, M. (2021) · The Japanese Journal of Sarcoidosis and Other Granulomatous Disorders · doi:10.7878/jjsogd.41.1_2_45
Zha, H., Si, G., Wang, C., Lv, J., Zhang, H., & Li, L. (2022) · Journal of Applied Microbiology · doi:10.1111/jam.15562
“For example, Bacteroides vulgatus and B. dorei were found to prevent coronary artery disease (Yoshida et al., 2018), while toxin from B. fragilis was a driver of colonic disease (Valguarnera & Wardenburg, 2020).”
BackgroundBeneficial role of gut microbiome in metabolic syndrome, obesity, and cardiovascular diseases
Banerjee, P., Choudhury, S., Jalan, K., Das, A., Ghosh, N., & Bagchi, D. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822238-6.00018-2
Traughber, C. A., Iacano, A. J., Khan, M. R., Neupane, K., Opoku, E., Nunn, T., Sangwan, N., Hazen, S. L., Smith, J. D., & Gulshan, K. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.22.504848
山下, 智., & Hirata, K. (2022) · Journal of JCS Cardiologists · doi:10.1253/jjcsc.31.0_63
Self-citationEffects of gut microbiota and gut-derived lipopolysaccharide on patients with coronary heart diseasePreprint
Liu, Y., Sheng, X., Wang, Z., Zheng, G., Chen, Z., & Jin, X. (2022) · Research Square · doi:10.21203/rs.3.rs-2028335/v1
Gut Microbiome Variation in Pulmonary TB Patients with Diabetes or HIV ComorbiditiesPreprint
Morgan, P. A., Parbie, P. K., Ntiamoah, D. O., Boadu, A. A., Asare, P. P. A., Lamptey, I. N. K., Gorman, C. N., Afreh, E. K., Asante-Poku, A., Otchere, I. D., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1756773/v2
5) Gut Microbiota in Cardiovascular Diseases
Yamashita, T., & Hirata, K. (2021) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.110.1848
Self-citationJin, J., Jing, N., Liu, F., Wang, R., Zhang, Y., Yang, J., Hou, Y., Zhang, H., Xie, Y., Liu, H., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2292353/v1
Faecalibacterium prausnitzii Reduces Plasma Lipopolysaccharide and Inhibits AtherosclerosisPreprint
Yang, H.-T., Liu, J., Wu, T., Yang, Y., Wu, C.-X., Hou, X., Zheng, Y., Ma, Y., & Xie, X. (2022) · Research Square · doi:10.21203/rs.3.rs-2391124/v1
Alteration of gut microbiota in post-stroke depression patients with Helicobacter pylori infectionPreprint
Cheng, H., Dong, S., Chen, H., Sun, M., Zhang, G., & Zhou, X. (2023) · Research Square · doi:10.21203/rs.3.rs-2740604/v1
Yiu, J. H. C., Cai, J., Cheung, S. W. M., Chin, K. T.-C., Chan, C. F., C., E., Sharma, R., Dorweiler, B., & Woo, C. W. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.04.539500
Advances in the Study of Risk Factors for Systemic Lupus Erythematosus with Atherosclerosis
崔, 天. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1371494
Effect of ursodeoxycholic acid on the intestinal microbiota in children with chronic liver disease
Васильевна, В. Г., Nikitin, A. V., Андреевна, С. Т., Потапов, А. С., Валерьевна, Д. В., & Danilov, L. G. (2023) · Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) · doi:10.21508/1027-4065-2023-68-3-46-54
Features of the gut microbiota in children with chronic liver diseases
Васильевна, В. Г., Потапов, А. С., Nikitin, A. V., Danilov, L. G., Андреевна, С. Т., & Валерьевна, Д. В. (2023) · Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) · doi:10.21508/1027-4065-66-xx
Tong, S., Lyu, Y., Luo, R., Leung, F. W., Sha, W., & Chen, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1287441
“Nonetheless, previous studies have been controversial on the role of Bacteroides dorei in different diseases (Zhang, Osaka and Tsuneda, 2015; Yao et al., 2018; Yoshida et al., 2018; Song et al., 2021), which suggested a disease speci fi c probiotic property of B. dorei .”
A comparative study of gut microbiota in the healthy elderly and the elderly with colorectal cancer
Iadsee, N. (2021) · Chula Digiverse · doi:10.58837/chula.the.2021.246
Additional file 7 of A 2 miRNAs-based signature for the diagnosis of atherosclerosis
Han, X., Wang, H., Li, Y., Liu, L., & Gao, S. (2021) · Figshare · doi:10.6084/m9.figshare.14300456
Additional file 10 of A 2 miRNAs-based signature for the diagnosis of atherosclerosis
Han, X., Wang, H., Li, Y., Liu, L., & Gao, S. (2021) · Figshare · doi:10.6084/m9.figshare.14300435
Additional file 8 of A 2 miRNAs-based signature for the diagnosis of atherosclerosis
Han, X., Wang, H., Li, Y., Liu, L., & Gao, S. (2021) · Figshare · doi:10.6084/m9.figshare.14300459
Additional file 9 of A 2 miRNAs-based signature for the diagnosis of atherosclerosis
Han, X., Wang, H., Li, Y., Liu, L., & Gao, S. (2021) · Figshare · doi:10.6084/m9.figshare.14300462
Additional file 6 of A 2 miRNAs-based signature for the diagnosis of atherosclerosis
Han, X., Wang, H., Li, Y., Liu, L., & Gao, S. (2021) · Figshare · doi:10.6084/m9.figshare.14300453
Sun, S., Wang, D., Dong, D., Xu, L., Xie, M., Wang, Y., Ni, T., Jiang, W., Zhu, X., Ning, N., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22623866
Yang, B., Shen, Z., Wang, M., Mei, L., Wu, Y., & Yu, X. (2024) · Research Square · doi:10.21203/rs.3.rs-4232293/v1
Human microbiome, obesity and cardiovascular diseases
Piansay‐Soriano, M. E., Soriano, S. K., Pague, B. V., Platero, M. S., Candelario-Plata, M. A., & Calunsag, M. K. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15435-5.00008-6
Microbiome and atherosclerosis
Fülöp, P., Vachalcová, M., Sepešiová, B., Harvanová, D., Šoltýs, K., & Valočík, G. (2024) · Vnitřní lékařství · doi:10.36290/vnl.2024.105
stana: an R package for metagenotyping analysis and interactive application based on clinical data
Sato, N., Katayama, K., Miyaoka, D., Uematsu, M., Saito, A., Fujimoto, K., Uematsu, S., & Imoto, S. (2025) · NAR Genomics and Bioinformatics · doi:10.1093/nargab/lqae191
“The species B. dorei in the gut microbiome has been reported to play a role in atherosclerosis through the reduction of LPS biosynthesis ( 22 ), and we suggested the possible role of functional differences of the corresponding species.”
Ren, H., Cao, X., Guo, X., & Yuan, P. (2025) · Israeli Journal of Aquaculture - Bamidgeh · doi:10.46989/001c.127435
3. Gut Microbiome and Cardiovascular Diseases
Hirata, K., & Yamashita, T. (2024) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.113.82a
Self-citationTao, Z., Li, J., Qian, P., Wu, G., Hu, K., Wen, Y., He, X., Fu, C., & Yu, L. (2025) · Food Science and Human Wellness · doi:10.26599/fshw.2025.9250533
Mesobiliverdin IXα-enriched microalgal feed supplement promotes beneficial gut microbiota in rabbits
Takemoto, J. Y., Hintze, K. J., Grilley, M. M., & Chang, C. T. (2025) · World Rabbit Science · doi:10.4995/wrs.2025.20748
Safety Assessment of Two Human Fecal Bacteroides Strain Isolates in Immunodeficient Mice
Jiang, B., Wang, Z., Wang, M., Wang, S., Li, M., Meng, Z., Yuan, J., & Ke, Y. (2025) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-025-10529-y
Su, J., Li, F., Bai, W., Ma, Z., & Peppelenbosch, M. P. (2025) · medRxiv · doi:10.1101/2025.04.10.25325255
张, 虎. (2025) · Journal of Clinical Personalized Medicine · doi:10.12677/jcpm.2025.43346
The role of constipation in the development of dyslipidemia in the elderly
Martynenko, A., & Nunes, S. P. (2025) · Fundamental and Clinical Medicine · doi:10.23946/2500-0764-2025-10-2-118-129
The Gut Microbiome and Cardiac Arrhythmias
Vautier, R. A. (2025) · Federal Practitioner · doi:10.12788/fp.0595
“13 If altering gut microbial composition can affect the disease process, it may indicate a causative role for gut dysbiosis in disease pathogenesis.”
Wang, M., Guo, Y., Cao, Z., Xu, Q., Chen, G., & Chen, Y. (2025) · Animals · doi:10.3390/ani15142122
Gut microbiota as a pharmacological target in cardiovascular diseases
Eslami, M., Banihashemian, S. Z., Alibabaei, F., Mohammadlou, M., & Babaeizad, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27370-4.00027-5 · Cited by 1
3. Gut Microbiome and Cardiovascular Diseases
Hirata, K., Emoto, T., & Yamashita, T. (2024) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.113.1525
Self-citationWhat Is the Involvement of Gut Microbiome in the Pathophysiology of Diabetes?
Kiełbowski, K., Plewa, P., Zadworny, J., Stodolak, P., Jędrasiak, A., Bakinowska, E., & Pawlik, A. (2025) · Biomolecules · doi:10.3390/biom15101463 · Cited by 1
Gao, S., Yang, M., Lu, Y., Sun, X., Qian, Y., Wang, H., Chen, T., Yang, Z., Du, Z., Ouyang, Y., et al. (2025) · medRxiv · doi:10.1101/2025.10.23.25338456
Virwani, P. D., Qian, G., Cheung, C. N.-M., Pijarnvanit, T. K. K. T. S., Hsu, M. S. S., Chow, Y. H., Lok Kan, T. A. N. G., Tse, Y.-H., Xian, J.-W., Shirley Sau-Wing, L. A. M., et al. (2026) · Gut Microbiome · doi:10.1017/gmb.2026.10026
Hsieh, C., Hsu, Y., Pan, T., & Lee, C. (2025) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.70342
Li, E., Saleem, F., Bello, S., Edge, T. A., Gupta, R. S., & Schellhorn, H. E. (2025) · Environments · doi:10.3390/environments12120495
“In this study, we identified a conserved signature protein unique to Phocaeicola dorei and Phocaeicola vulgatus , two commensal species commonly found in the human gut and feces [53], and then developed a qPCR assay targeting this CSP gene (designated as CSP-DV) as a proxy for human fecal pollution.”
Matsuoka, T., Shimizu, T., Minagawa, T., Hiranuma, W., Takeda, M., Kakuta, R., & Kawamoto, S. (2021) · Figshare · doi:10.6084/m9.figshare.14889405
Additional file 2 of A 2 miRNAs-based signature for the diagnosis of atherosclerosis
Han, X., Wang, H., Li, Y., Liu, L., & Gao, S. (2021) · Figshare · doi:10.6084/m9.figshare.14300441
Additional file 3 of A 2 miRNAs-based signature for the diagnosis of atherosclerosis
Han, X., Wang, H., Li, Y., Liu, L., & Gao, S. (2021) · Figshare · doi:10.6084/m9.figshare.14300444
Additional file 10 of Faecalibacterium prausnitzii as a potential Antiatherosclerotic microbe
Yang, H.-T., Jiang, Z.-H., Yang, Y., Wu, T.-T., Zheng, Y.-Y., Ma, Y.-T., & Xie, X. (2024) · Figshare · doi:10.6084/m9.figshare.26669604
Additional file 3 of Faecalibacterium prausnitzii as a potential Antiatherosclerotic microbe
Yang, H.-T., Jiang, Z.-H., Yang, Y., Wu, T.-T., Zheng, Y.-Y., Ma, Y.-T., & Xie, X. (2024) · Figshare · doi:10.6084/m9.figshare.26669583
Additional file 4 of A 2 miRNAs-based signature for the diagnosis of atherosclerosis
Han, X., Wang, H., Li, Y., Liu, L., & Gao, S. (2021) · Figshare · doi:10.6084/m9.figshare.14300447
Additional file 6 of Faecalibacterium prausnitzii as a potential Antiatherosclerotic microbe
Yang, H.-T., Jiang, Z.-H., Yang, Y., Wu, T.-T., Zheng, Y.-Y., Ma, Y.-T., & Xie, X. (2024) · Figshare · doi:10.6084/m9.figshare.26669592
Sun, S., Wang, D., Dong, D., Xu, L., Xie, M., Wang, Y., Ni, T., Jiang, W., Zhu, X., Ning, N., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22623872
Sun, S., Wang, D., Dong, D., Xu, L., Xie, M., Wang, Y., Ni, T., Jiang, W., Zhu, X., Ning, N., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22623899
Sun, S., Wang, D., Dong, D., Xu, L., Xie, M., Wang, Y., Ni, T., Jiang, W., Zhu, X., Ning, N., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22623878
Additional file 5 of A 2 miRNAs-based signature for the diagnosis of atherosclerosis
Han, X., Wang, H., Li, Y., Liu, L., & Gao, S. (2021) · Figshare · doi:10.6084/m9.figshare.14300450
Lee, A. H., Jha, A. R., Do, S., Scarsella, E., Shmalberg, J. W., Schauwecker, A., Steelman, A. J., Honaker, R. W., & Swanson, K. S. (2022) · Figshare · doi:10.6084/m9.figshare.21756693
Additional file 1 of A 2 miRNAs-based signature for the diagnosis of atherosclerosis
Han, X., Wang, H., Li, Y., Liu, L., & Gao, S. (2021) · Figshare · doi:10.6084/m9.figshare.14300438
Sun, S., Wang, D., Dong, D., Xu, L., Xie, M., Wang, Y., Ni, T., Jiang, W., Zhu, X., Ning, N., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22623863
Matsuoka, T., Shimizu, T., Minagawa, T., Hiranuma, W., Takeda, M., Kakuta, R., & Kawamoto, S. (2021) · Figshare · doi:10.6084/m9.figshare.14889408
Sun, S., Wang, D., Dong, D., Xu, L., Xie, M., Wang, Y., Ni, T., Jiang, W., Zhu, X., Ning, N., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22623890
Sun, S., Wang, D., Dong, D., Xu, L., Xie, M., Wang, Y., Ni, T., Jiang, W., Zhu, X., Ning, N., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22623887
Additional file 8 of Faecalibacterium prausnitzii as a potential Antiatherosclerotic microbe
Yang, H.-T., Jiang, Z.-H., Yang, Y., Wu, T.-T., Zheng, Y.-Y., Ma, Y.-T., & Xie, X. (2024) · Figshare · doi:10.6084/m9.figshare.26669598
Sun, S., Wang, D., Dong, D., Xu, L., Xie, M., Wang, Y., Ni, T., Jiang, W., Zhu, X., Ning, N., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22623881
Sun, S., Wang, D., Dong, D., Xu, L., Xie, M., Wang, Y., Ni, T., Jiang, W., Zhu, X., Ning, N., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22623896
Lee, A. H., Jha, A. R., Do, S., Scarsella, E., Shmalberg, J. W., Schauwecker, A., Steelman, A. J., Honaker, R. W., & Swanson, K. S. (2022) · Figshare · doi:10.6084/m9.figshare.21756690
Kim, J.-A., Jang, B.-R., Kim, Y.-R., Jung, Y.-C., Kim, K.-S., & Lee, K.-H. (2021) · Figshare · doi:10.6084/m9.figshare.15026565
Additional file 7 of Faecalibacterium prausnitzii as a potential Antiatherosclerotic microbe
Yang, H.-T., Jiang, Z., Yang, Y., Wu, T.-T., Zheng, Y.-Y., Ma, Y.-T., & Xie, X. (2024) · Figshare · doi:10.6084/m9.figshare.26669595
Additional file 1 of Faecalibacterium prausnitzii as a potential Antiatherosclerotic microbe
Yang, H.-T., Jiang, Z., Yang, Y., Wu, T.-T., Zheng, Y.-Y., Ma, Y.-T., & Xie, X. (2024) · Figshare · doi:10.6084/m9.figshare.25034401
Sun, S., Wang, D., Dong, D., Xu, L., Xie, M., Wang, Y., Ni, T., Jiang, W., Zhu, X., Ning, N., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22623875
Sun, S., Wang, D., Dong, D., Xu, L., Xie, M., Wang, Y., Ni, T., Jiang, W., Zhu, X., Ning, N., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22623893
Additional file 2 of Faecalibacterium prausnitzii as a potential Antiatherosclerotic microbe
Yang, H.-T., Jiang, Z.-H., Yang, Y., Wu, T.-T., Zheng, Y.-Y., Ma, Y.-T., & Xie, X. (2024) · Figshare · doi:10.6084/m9.figshare.25034496
Additional file 4 of Faecalibacterium prausnitzii as a potential Antiatherosclerotic microbe
Yang, H.-T., Jiang, Z.-H., Yang, Y., Wu, T.-T., Zheng, Y.-Y., Ma, Y.-T., & Xie, X. (2024) · Figshare · doi:10.6084/m9.figshare.26669586
Additional file 9 of Faecalibacterium prausnitzii as a potential Antiatherosclerotic microbe
Yang, H.-T., Jiang, Z., Yang, Y., Wu, T.-T., Zheng, Y.-Y., Ma, Y.-T., & Xie, X. (2024) · Figshare · doi:10.6084/m9.figshare.26669601
Additional file 5 of Faecalibacterium prausnitzii as a potential Antiatherosclerotic microbe
Yang, H.-T., Jiang, Z.-H., Yang, Y., Wu, T.-T., Zheng, Y.-Y., Ma, Y.-T., & Xie, X. (2024) · Figshare · doi:10.6084/m9.figshare.26669589
Özdemir, Ö., Ertürk, Ö., & Görgün, S. (2026) · Journal of Investigative Medicine · doi:10.1177/10815589251413252
“36 Many studies stated the association of the gut microbiota and IR.”
Zhang, Y., Wang, J., Wang, Z. T., Liu, Y., Wang, Y., Fu, Z., Zhao, X., Xu, P., Zheng, Z., Xu, Z., et al. (2026) · Advanced Healthcare Materials · doi:10.1002/adhm.202504623
Bian, R., Zhang, L., Zhu, J., & Xu, X. (2026) · Food Science & Nutrition · doi:10.1002/fsn3.71543
“A notable mechanistic finding of this study is the remodeling of the gut microbiota–bile acid axis (Yoshida et al. 2018).”
Chen, J., Fan, Z., Li, Y., Duan, R., & Gao, B. (2026) · iScience · doi:10.1016/j.isci.2026.115490
“203 Beyond these bacterial shifts, exercise also enhances gut buty-rate production in patients with T2D.”
Impact du microbiome intestinal sur la cholestérolémie : concepts et applications
Bourgin, M. (2021) · theses.fr (ABES) · doi:10.70675/5ef61a78z31c7z44fazafa1zd4a5749a4aaf
Microbiote intestinal et vitamines B dans l’obésité sévère : le cas de la biotine
Voland, L. (2022) · theses.fr (ABES) · doi:10.70675/3d6ab2f6z3844z4eccz9cbazdd1ace927949
Metadata
- Authors
- Yoshida, N., Emoto, T., Yamashita, T., Watanabe, H., Hayashi, T., Tabata, T., Hoshi, N., Hatano, N., Ozawa, G., Sasaki, N., Mizoguchi, T., Amin, H. Z., Hirota, Y., Ogawa, W., Yamada, T., & Hirata, K.-I.
- Affiliations
- Kobe University (JP)
- Tokyo Institute of Technology (JP)
- Technosuruga Laboratory Co., Ltd. (Japan) (JP)
- University of Indonesia (ID)
- Corresponding author
- Yoshida, Naofumi
- Emoto, Takuo
- ORCID
- Venue
- Circulation
- Published
- 2018-11-27
- Volume
- 138
- Issue
- 22
- Pages
- 2486-2498
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2886282415
- Cited by
- 619
- References
- 50
- Citations by year
- 2026: 52 · 2025: 105 · 2024: 112 · 2023: 113 · 2022: 101 · 2021: 75 · 2020: 47 · 2019: 13 · 2018: 1
- FWCI
- 12.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Kobe University Repository Kernel (Kobe University) (submittedVersion)
- Funders
- Japan Society for the Promotion of Science (16H06279)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- Bacteroides vulgatus, Bacteroides dorei, gut microbiota, atherosclerosis, coronary artery disease, lipopolysaccharide, endotoxemia, pro-inflammatory response, fecal microbiota transplantation, gut-heart axis
- MeSH terms
- Gastrointestinal Microbiome, Aged, Animals, Bacteroides, Feces, Female, Humans, Intestines, Lipopolysaccharides, Male, Mice, Inbred C57BL, Middle Aged, Risk Factors, RNA, Ribosomal, 16S, Sequence Analysis, RNA, Mice, Knockout, Immunity, Mucosal, Tight Junctions, Atherosclerosis, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
